SES
18.7.2022 08:52:08 CEST | Business Wire | Press release
SES, the world’s leading content connectivity satellite service provider, today announced that it will be providing global connectivity services to Explora Journeys, debuting on EXPLORA I. Guests and crew will benefit from SES’s best-in-class low latency, highest available throughput and global Cruise mPOWERED connectivity service.
Explora Journeys, the new luxury lifestyle brand of the MSC Group, is redefining the ocean experience for a new generation of discerning luxury travellers. The brand’s aspiration is to create a unique ‘Ocean State of Mind’ by connecting guests with the sea, with themselves, and with like-minded people, while remarkable itineraries will blend renowned destinations with lesser-travelled ports, for a journey that inspires discovery in all its forms.
Today’s announcement means that guests onboard the EXPLORA I will enjoy complementary, high-speed, reliable, and uninterrupted Wi-Fi, no matter how remote their location. Whether they are streaming their favourite content or sharing their onboard experience from any part of the ship. In addition, enhanced connectivity will improve crew welfare and training, employee performance, motivation, and retention.
This connectivity is delivered by SES’s upcoming second-generation medium earth orbit (MEO) system - O3b mPOWER - which operates around 8,000km above earth’s surface, and SES’s geostationary (GEO) fleet of satellites ensuring seamless connectivity, wherever and whenever.
Michael Ungerer, CEO of Explora Journeys commented, “High-speed, reliable and uninterrupted connectivity is no longer a ‘nice to have’, with demand for connectivity services at sea growing in tandem with the development of social media platforms. Today’s guests simply expect seamless and uninterrupted connectivity comparable to on land as they want to share their experiences and stay online as much as possible. We are pleased to be able to offer this connectivity experience to our guests onboard Explora I thanks to SES’s services.”
Simon Maher, Vice President Global Sales, Cruise Maritime Services at SES, said, “It is incredibly exciting to be working with Explora Journeys whose innovative approach is setting new standards in ultra-luxury curated travel experiences at sea. Connectivity is one of the most important enablers for such travel experiences from both a guest and crew point of view. Our O3b mPOWER ultra-fast, low-latency connectivity is empowering a new experience that will revolutionise the ultra-luxury expedition maritime segment.”
Follow us on:
Twitter | Facebook | YouTube | LinkedIn | Instagram
Read our Blogs
>
Visit the Media Gallery
>
About SES
SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries almost 8,200 channels and has an unparalleled reach of 367 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com .
About Explora Journeys
Explora Journeys is redefining ocean travel for a new generation of discerning explorers. With the first of four luxury ships scheduled to set sail in 2023, remarkable itineraries will blend renowned destinations with lesser-travelled ports for a journey that celebrates discovery. Whether on board or ashore, guests will reconnect with what matters most—themselves, their loved ones, and the world around them. With 461 oceanfront suites, every guest will enjoy sweeping sea views and a private terrace, while being spoilt for choice with nine distinct restaurants providing unrivalled variety at sea. Equipped with the latest in environmental-supporting and marine technologies, Explora Journeys will introduce a unique luxury travel experience for those who want to explore differently. To learn more about Explora Journeys, visit ExploraJourneys.com or follow along on Instagram , Twitter , Facebook and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220712006039/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom